clinical trial · NCT04749914
A Study of Lasmiditan in Healthy Volunteers
Eli Lilly and Company·phase1·completed·n = 97
HealthyLasmiditanDabigatran EtexilateRosuvastatin
brief summary
The main purpose of the study is to investigate the blood concentrations of dabigatran etexilate and rosuvastatin when taken alone compared to when taken together with lasmiditan in healthy participants. The safety and tolerability of dabigatran etexilate or rosuvastatin in combination with lasmiditan will also be evaluated in healthy participants. The study has two parts. Each part will last up to 17 days, not including screening.
started
Feb 15, 2021
primary completion
Jul 6, 2021
completion
Jul 6, 2021
last updated
Feb 1, 2024
official title
An Open-Label, 2-Part Study to Investigate the Effect of Lasmiditan on the Pharmacokinetics of Dabigatran and Rosuvastatin in Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol